
AGTC: A biotech firm conducting clinical trials for AAV-based gene therapies for rare diseases.
AGTC, a biotechnology company, focuses on developing AAV-based gene therapies to treat rare diseases. Founded with the mission to transform lives through pioneering ocular gene therapy, AGTC is dedicated to saving and restoring vision for patients suffering from various prevalent and rare ophthalmic conditions. The company is currently conducting human clinical trials, including the VISTA trial for X-Linked Retinitis Pigmentosa, and offers no-cost genetic testing and prescreening for eligible participants.
Notable figures affiliated with AGTC include experienced scientists and researchers in the field of gene therapy. The company has garnered significant investment from leading biotech venture capital firms. Key achievements include advancing multiple gene therapy candidates into clinical trials and making substantial progress in the treatment of rare ocular diseases. AGTC's innovative approach has had a profound impact on the biotechnology landscape, offering hope to patients with previously untreatable conditions.

American Gene Technologies International
americangene.com

Apertura Gene Therapy
aperturagtx.com

Jaguar Gene Therapy

Aavogen
aavogen.com

Regenxbio
regenxbio.com

Atsena Therapeutics
atsenatx.com

Opus Genetics
opusgtx.com

Editas Medicine

RainBio
rainbio.us

MeiraGTx Holdings
meiragtx.com

Taysha Gene Therapies
tayshagtx.com

Lacerta Therapeutics

BioViva

Oculogenex
oculogenex.com

Solid Biosciences
solidbio.com
Companies similar to Agtc include American Gene Technologies International, Apertura Gene Therapy, Jaguar Gene Therapy and Aavogen.
Agtc was founded in 1999.
Agtc's headquarters is located in Alachua, FL, US.
Agtc's most recent funding round was for $10M (USD) in July 2022.
As of Jul 12, 2022, Agtc has raised a total of $195.1M (USD).
Agtc has 350 employees as of Feb 5, 2024.